From the Department of Laboratory Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria (Cadamuro, Haschke-Becher, Keppel, Oberkofler, Felder, Mrazek).
The Department of Medical Laboratory Diagnostics, Faculty of Pharmacy and Biochemistry, University Hospital Sveti Duh, University of Zagreb, Zagreb, Croatia (Simundic).
Arch Pathol Lab Med. 2023 Jan 1;147(1):117-124. doi: 10.5858/arpa.2021-0283-OA.
CONTEXT.—: Underuse of laboratory testing has been previously investigated in preselected populations, such as documented malpractice claims. However, these numbers might not reflect real-life situations.
OBJECTIVE.—: To evaluate the underuse and misuse of laboratory follow-up testing in a real-life hospital patient population with microcytic anemia, using laboratory results ordered during routine patient care.
DESIGN.—: From all patients in whom a microcytic anemia was detected during routine diagnostics in 2018, all available laboratory data were collected and screened for appropriateness of diagnostic workup of iron deficiency and thalassemia. Subgroup analysis was performed for patient groups with mean corpuscular volume values 75 to 79 μm3 (group 1), 65 to 74 μm3 (group 2), and <65 μm3 (group 3).
RESULTS.—: A total of 2244 patients with microcytic anemia were identified. Follow-up testing for iron deficiency was not performed in 761 cases (34%). For inconclusive ferritin levels due to elevated C-reactive protein results (n = 336), reticulocyte hemoglobin content or soluble transferrin receptor levels were missing in 86 cases (26%). In patients with suspected thalassemia (n = 127), follow-up testing for hemoglobin variants was not performed in 70 cases (55%). Subgroup analysis showed that the frequency of underuse of iron status as well as thalassemia/hemoglobinopathy testing decreased from group 1 to group 3. When considering relevant preexisting anemia diagnoses, laboratory tests were underused in 904 cases (40.3%).
CONCLUSIONS.—: Because 40% (n = 904) of the patients with microcytic anemia were potentially not followed up correctly, laboratory specialists are advised to act by implementing demand management strategies in collaboration with clinicians to overcome underuse of laboratory tests and to improve patient safety.
实验室检测的不充分使用已在预选人群中进行了研究,例如有记录的医疗事故索赔。然而,这些数字可能无法反映实际情况。
通过在常规患者护理中使用实验室检测结果,评估在真实医院患者微小型贫血人群中进行实验室随访检测的不足和误用。
从 2018 年常规诊断中发现微小型贫血的所有患者中,收集了所有可用的实验室数据,并对缺铁和地中海贫血的诊断检查的适当性进行了筛选。对平均红细胞体积值为 75 至 79μm3(组 1)、65 至 74μm3(组 2)和 <65μm3(组 3)的患者组进行了亚组分析。
共确定了 2244 例微小型贫血患者。761 例(34%)未进行缺铁随访检测。由于 C 反应蛋白结果升高导致铁蛋白水平不确定(n=336),86 例(26%)缺少网织红细胞血红蛋白含量或可溶性转铁蛋白受体水平。在疑似地中海贫血的患者(n=127)中,70 例(55%)未进行血红蛋白变异的随访检测。亚组分析表明,从组 1 到组 3,铁状态和地中海贫血/血红蛋白病检测的不足使用频率降低。当考虑相关的现有贫血诊断时,904 例(40.3%)患者的实验室检测不足。
由于 40%(n=904)的微小型贫血患者可能未得到正确的随访,因此建议实验室专家通过与临床医生合作实施需求管理策略来克服实验室检测的不足,并提高患者安全性。